药物性肝损伤治疗的进展与困惑  

Drug-induced liver injury:Advances and confusions in treatment

作　　者：陈帅 杨长青[1] CHEN Shuai;YANG Changqing(Department of Gastroenterology,Tongji Hospital Affiliated to Tongji University,Shanghai 200065,China)

机构地区：[1]同济大学附属同济医院消化内科,上海200065

出　　处：《临床肝胆病杂志》2021年第11期2505-2509,共5页Journal of Clinical Hepatology

基　　金：国家自然科学基金项目(81670571,81820108006);上海市临床重点专科建设项目(SHSLCZDZK06801);上海申康三年行动计划重大临床研究项目(SHDC2020CR203B)。

摘　　要：药物性肝损伤(DILI)是最常见、最严重的药物不良反应之一,严重者可引起急性肝衰竭甚至死亡。DILI发病机制尚未完全阐明,个体差异较显著,晚期DILI除肝移植外尚无有效的治疗方法,因此早期诊断、精准治疗显得尤为重要。现就近年来DILI治疗领域重要研究进展和难点问题进行述评。Drug-induced liver injury(DILI)is one of the most common and serious adverse drug reactions and can lead to acute liver failure and even death in severe cases.The pathogenesis of DILI has not been fully clarified,and there is significant individual difference.There is no effective treatment for advanced DILI except liver transplantation,and therefore,early diagnosis and precise treatment are of particular importance.This article reviews the important research advances and difficult issues in the treatment of DILI in recent years.

关 键 词：化学性与药物性肝损伤 治疗学 预后 

分 类 号：R575[医药卫生—消化系统]